Literature DB >> 3626537

An assessment of monocyte procoagulant activity in patients with solid tumors.

K S Dasmahapatra, N K Cheung, C Spillert, E Lazaro.   

Abstract

Generation of thromboplastin by monocytes has been shown to play a vital role in hypercoagulable states seen in malignancy. The purpose of this study was to compare the procoagulant activity in cancer patients and controls. Recalcification times (RT) of whole blood from 19 normal volunteers, 8 patients with benign polyps, 12 patients previously treated by surgery for head and neck (H&N) or colon cancer, and 13 untreated patients with various stages of H&N or colon cancer were determined. Tests were performed with and without stimulation with Escherichia coli endotoxin. The mean RT in saline (RTS) of untreated patients with early cancer (4.58 +/- 0.83 min) and that of patients with advanced cancer (5.23 +/- 1.16 min) were lower than that of controls (6.55 +/- 0.82 min), P less than 0.01 and P less than 0.05, respectively. The RTS of patients previously treated and of those with benign polyps were no different from those of controls. Activation with endotoxin significantly lowered the recalcification times (RTE) in the early (3.90 +/- 0.58 min) and advanced cancer patients (4.23 +/- 0.66 min) compared to the RTE of controls (5.69 +/- 0.75 min, P less than 0.01 for both groups) as well as compared to those with benign tumors, P less than 0.05. The mean RTE of previously treated patients (4.72 +/- 0.58 min) was also lower than that of controls, P less than 0.05. Our results suggest that RT is significantly reduced in cancer patients compared to that of controls. Furthermore, monocyte activation with endotoxin may enable us to distinguish cancer patients from controls as well as from those with benign tumors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3626537     DOI: 10.1016/0022-4804(87)90159-4

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  14 in total

1.  Effect of methylprednisolone on coagulation.

Authors:  H B Pandit; C R Spillert
Journal:  J Natl Med Assoc       Date:  1999-08       Impact factor: 1.798

2.  Contribution of the monocyte to thrombotic potential.

Authors:  C R Spillert; E J Lazaro
Journal:  Agents Actions       Date:  1991-09

3.  Modified recalcification time (MRT): a sensitive cancer test? Review of the evidence.

Authors:  C R Spillert; E J Lazaro
Journal:  J Natl Med Assoc       Date:  1995-09       Impact factor: 1.798

4.  Altered coagulability: an aid to selective breast biopsy.

Authors:  C R Spillert; M R Passannante; J E Salzer-Pagan; E J Lazaro
Journal:  J Natl Med Assoc       Date:  1993-04       Impact factor: 1.798

5.  Trousseau's syndrome.

Authors:  N Callander; S I Rapaport
Journal:  West J Med       Date:  1993-04

6.  In vitro effect of hirudin on recalcification time.

Authors:  J Hirsh; C R Spillert; E P Delle Donne; E J Lazaro
Journal:  J Natl Med Assoc       Date:  1994-08       Impact factor: 1.798

7.  Whole blood procoagulant activity in breast and colorectal cancer.

Authors:  H Mellor; I Taylor; S Roath; J L Francis
Journal:  J Clin Pathol       Date:  1989-05       Impact factor: 3.411

Review 8.  Cardiopulmonary bypass in patients with pre-existing coagulopathy.

Authors:  William DeBois; Junli Liu; Leonard Lee; Leonard Girardi; Wilson Ko; Anthony Tortolani; Karl Krieger; O Wayne Isom
Journal:  J Extra Corpor Technol       Date:  2005-03

9.  Hypertension-related coronary thrombosis: prothrombic role of angiotensin II.

Authors:  C R Spillert; S Sun; M A Miller; E J Lazaro
Journal:  J Natl Med Assoc       Date:  1994-09       Impact factor: 1.798

Review 10.  Tissue factor as a tumor procoagulant.

Authors:  L V Rao
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.